REC-163964 is under clinical development by Recursion Pharmaceuticals and currently in Phase I for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase I drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how REC-163964’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
REC-163964 is under development for the treatment of clostridium difficile colitis. The drug candidates are repurposed drugs developed based on combination of artificial intelligence, automation and experimental biology. It is administered through oral route. It acts as selectively inhibitor of clostridium difficile toxins.
Recursion Pharmaceuticals overview
Recursion Pharmaceuticals (Recursion) is an artificial intelligence (AI)-driven biopharmaceutical company. It harnesses the potential of applying machine learning (ML) to complex biology to advance novel treatment options for diseases with high unmet medical needs. The company houses over four petabytes of biological images on its robotics platform which applies advanced ML to identify drug candidates and provide insights on potential toxicity, and mechanisms of action. It is advancing a pipeline of cardiovascular, metabolic, oncology, immunology, neuroscience, and infectious disease models. The company also offers target discovery and lead optimization services to its partner companies for furthering their clinical investigation. Recursion is headquartered in Salt Lake City, Utah, the US.
For a complete picture of REC-163964’s drug-specific PTSR and LoA scores, buy the report here.